ORGO
NASDAQ
US
Organogenesis Holdings Inc. - Class A
$2.24
▼ $-0.07
(-3.03%)
Vol 507K
12
Quality Score
ok
Deep Check
1/5
fail
Rev ✗
NI ✓
>IPO ✗
Mkt Cap
$657.4M
P/E
654.1
ROE
0.3%
Margin
0.2%
D/E
0.86
Beta
1.50
52W
$3–$7
Wall Street Consensus
7 analysts · Apr 20263
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
NBP
NovaBridge Biosciences
$458.9M
AVXL
Anavex Life Sciences Corp
$318.1M
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
ABEO
Abeona Therapeutics Inc
P/E 3.5
$285.6M
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.30
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.30 | — | — |
| Dec 2025 | $0.21 | $0.31 | +$0.10 |
| Sep 2025 | $0.06 | $0.15 | +$0.09 |
| Jun 2025 | $-0.06 | $-0.10 | $-0.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $126.7M | $86.7M | $100.8M | $150.5M | $225.1M |
| Net Income | — | $7.7M | -$18.8M | -$9.4M | $21.6M | $43.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -2.4% | -2.4% | -2.4% | -2.4% | 0.3% | 0.3% |
| P/E (TTM) | — | — | — | — | 635.19 | 654.13 |
| Net Margin | -9.3% | -1.9% | -1.9% | -1.9% | 0.2% | 0.2% |
| Gross Margin | 72.6% | 74.6% | 74.6% | 74.6% | 74.5% | 74.5% |
| D/E Ratio | 0.36 | 0.36 | 0.36 | 0.36 | 0.86 | 0.86 |
| Current Ratio | 3.95 | 3.95 | 3.95 | 3.95 | 3.32 | 3.32 |
Key Ratios
ROA (TTM)
0.2%
P/S (TTM)
1.41
P/B
1.0
EPS (TTM)
$0.00
CF/Share
$0.20
Rev Growth 3Y
+1.0%
52W High
$7.08
52W Low
$2.61
$2.61
52-Week Range
$7.08
Financial Health
Free Cash Flow
$34.8M
Net Debt
-$11.5M
Cash
$93.7M
Total Debt
$82.1M
As of Dec 31, 2025
How does ORGO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ORGO valuation vs Biotechnology peers
P/E ratio
654.1
▲
3383%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.4
▼
89%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.0
▼
58%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ORGO profitability vs Biotechnology peers
ROE
0.3%
▲
100%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
0.2%
▲
100%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
74.5%
▼
5%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
0.2%
▲
100%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ORGO financial health vs Biotechnology peers
D/E ratio
0.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
3.3
▼
25%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.5
▲
54%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ORGO fundamentals radar
ORGO
Peer median
Industry
ORGO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ORGO vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
LEIBOWITZ ARTHUR S
Director · Mar 09
5000 shs
DRISCOLL MICHAEL JOSEPH
Director · Mar 09
10000 shs
KORFIN MICHELE ILENE
Director · Feb 18
48828 shs
DURAIBABU PRATHYUSHA
Director · Feb 18
48828 shs
FRANCISCO DAVID
Chief Financial Officer · Feb 18
238914 shs
FRANCISCO DAVID
Chief Financial Officer · Feb 18
239352 shs
DRISCOLL MICHAEL JOSEPH
Director · Feb 18
48828 shs
QUINTERO GILBERTO
Director · Feb 18
48828 shs
CAVORSI ROBERT
Officer · Feb 18
110204 shs
LUSTIG GARRETT
Director · Feb 18
48828 shs
Last 90 days
Top Holders
Top 5: 28.66%Morgan Stanley
9.05%
$26.7M
Soleus Capital Management, …
7.76%
$22.9M
Assenagon Asset Management …
4.30%
$12.7M
Vanguard Group Inc
3.85%
$11.4M
Blackrock Inc.
3.70%
$10.9M
As of Dec 31, 2025